CoChat
Sign Up
Cited by 998Schizophrenia research and treatmentNeurotransmitter Receptor Influence on BehaviorTreatment of Major Depression

The DOI matches its Crossref record; 390 of the 393 references it cites were found in a registry or an index.

Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs

Miyamoto, S, Duncan, G E, Marx, C E, Lieberman, J A·2005·Molecular Psychiatry
DOI 10.1038/sj.mp.4001556
Open this paper in CoChat — free account

Abstract

The treatment of schizophrenia has evolved over the past half century primarily in the context of antipsychotic drug development. Although there has been significant progress resulting in the availability and use of numerous medications, these reflect three basic classes of medications (conventional (typical), atypical and dopamine partial agonist antipsychotics) all of which, despite working by varying mechanisms of actions, act principally on dopamine systems. Many of the second-generation (atypical and dopamine partial agonist) antipsychotics are believed to offer advantages over first-generation agents in the treatment for schizophrenia. However, the pharmacological properties that confer the different therapeutic effects of the new generation of antipsychotic drugs have remained elusive, and certain side effects can still impact patient health and quality of life. Moreover, the efficacy of antipsychotic drugs is limited prompting the clinical use of adjunctive pharmacy to augment the effects of treatment. In addition, the search for novel and nondopaminergic antipsychotic drugs has not been successful to date, though numerous development strategies continue to be pursued, guided by various pathophysiologic hypotheses. This article provides a brief review and critique of the current therapeutic armamentarium for treating schizophrenia and drug development strategies and theories of mechanisms of action of antipsychotics, and focuses on novel targets for therapeutic agents for future drug development.

Overview

Integrity signals

Registry

Crossref · 10.1038/sj.mp.4001556

Cites

390 of 390 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Flagged first, then by citations

3 of the 393 references couldn’t be matched to a known paper.

Research works printed but not linked: 15

  1. Breier A, Wright P, Birkett M, Meehan K, David, Brook S . A double-blind dose response study comparing intramuscular olanzapine, haloperidol and placebo in acutely agitated schizophrenic patients, ACNP 39th Annual Meeting Abstract. American College of Neuropsychopharmacology: Puerto Rico, 2000.
  2. Waddington J, Casey D . Comparative pharmacology of classical and novel (second-generation) antipsychotics. In: Buckley PF, Waddington JL (eds). Schizophrenia and Mood Disorders: The New Drug Therapies in Clinical Practice. Butterworth-Heinemann: Woburn, MA, 2000, pp 3–13.
  3. Carlsson A . Focusing on dopaminergic stabilizers and 5-HT2A receptor antagonists. Curr Opin CPNS Invest Drugs 2000; 2: 22–24.
  4. Patel JK, Pinals DA, Breier A . Schizophrenia and other psychoses. In: Tasman A, Kay J, Lieberman JA (eds). PSYCHIATRY, 2nd edn. John Wiley & Sons, Ltd: Chichester, 2003, pp 1131–1206.
  5. Ferris P . Ziprasidone. Curr Opin CPNS Invest Drugs 2000; 2: 58–70.
  6. Nichols DE, Mailman RB . Substituted hexa-hydro[a]phenanthridines. US Patent 1995; 5: 134.
  7. Nichols DE, Mailman RB . Fused isoquinolines as dopamine receptor ligands. US Patent 1999; 5: 110.
  8. Danysz W . Sonepiprazole. Curr Opin CPNS Invest Drugs 2000; 2: 97–104.
  9. Mansbach RS, Brooks EW, Sanner MA, Zorn SH . Selective dopamine D4 receptor antagonists reverse apomorphine-induced blockade of prepulse inhibition. Psychopharmacology 1998; 135: 194–200. · DOI
  10. Abi-Saab WM, D'Souza DC, Madonick SH, Krystal JH . Targeting the glutamate system. In: Breier A, Tran PV, Herrera JM, Tollefson GD, Bymaster FP (eds). Current Issues in the Psychopharmacology of Schizophrenia. Lippincott Williams & Wilkins Healthcare, Philadelphia, 2001, pp 304–332.
  11. Goff D, Berman I, Posever T, Leahy L, Lynch G . A preliminary dose-escalation trial of CX 516 (ampakine) added to clozapine in schizophrenia. Schizophr Res 1999; 36: 280.
  12. Bymaster FP . Possible role of muscarinic receptor agonists as therapeutic agents for psychosis. In: Breier A, Tran PV, Herrera JM, Tollefson GD, Bymaster FP (eds). Current Issues in the Psychopharmacology of Schizophrenia. Lippincott Williams & Wilkins Healthcare, Philadelphia, 2001, pp 333–348.
  13. Perry KW, Bymaster FP, Shannon HE, Rasmussen K, DeLapp NW, Zhang W et al. The muscarinic agonist xanomeline has antipsychotic-like activity in animals and in man. Schizophr Res 1999; 36: 117–118.
  14. Basile VS, Masellis M, Ozdemir V, Meltzer HY, Macciardi FM, Kennedy JL . Application of pharmacogenetics to schizophrenia: Emerging insights from studies of clozapine response and tardive dyskinesia. In: Breier A, Tran PV, Herrera JM, Tollefson GD, Bymaster FP (eds). Current Issues in the Psychopharmacology of Schizophrenia. Lippincott Williams & Wilkins Healthcare, Philadelphia, 2001, pp 85–110.
  15. Stroup TS, McEvoy JP, Swartz MS, Byerly MJ, Glick ID, Canive JM et al. The National Institute of Mental Health Clinical Antipsychotic Trials in Intervention Effectiveness (CATIE) Project: Schizophrenia trial design and protocol development. Schizophrenia Bull 2003; 29: 15–31. · DOI

Cited by

Sorted by citations

See all 998

Related

See all

Metadata

Authors
Miyamoto, S., Duncan, G. E., Marx, C. E., & Lieberman, J. A.
Affiliations
  • St. Marianna University School of Medicine (JP)
  • University of North Carolina at Chapel Hill (US)
  • Duke Medical Center (US)
Corresponding author
Lieberman, J A
Venue
Molecular Psychiatry
Publisher
Springer Science and Business Media LLC
Published
2004-08-03
Volume
10
Issue
1
Pages
79-104
ISSN
  • 1359-4184 (ISSN-L)
  • 1476-5578
DOI
10.1038/sj.mp.4001556
OpenAlex
W2132980997
Cited by
988
References
393
Citations by year
2026: 23 · 2025: 25 · 2024: 32 · 2023: 40 · 2022: 37 · 2021: 40 · 2020: 45 · 2019: 42 · 2018: 40 · 2017: 41 · 2016: 54 · 2015: 52 · 2014: 46 · 2013: 72 · 2012: 66
FWCI
4.72
Type
journal article
Language
en
Open access
closed
Licence
Locations
  • Molecular Psychiatry (publishedVersion)
  • PubMed (publishedVersion)
Funders
National Institute of Mental Health (MH064065, P50MH064065)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
Keywords
schizophrenia, antipsychotic drugs, dopamine D2 receptor, atypical antipsychotics, partial dopamine agonist, typical antipsychotics, mechanism of action, antipsychotic adverse effects, adjunctive pharmacotherapy, antipsychotic drug development, schizophrenia pathophysiology
MeSH terms
Behavioral Symptoms, Humans, Schizophrenia, Antipsychotic Agents, Drug Design, Dopamine Agents, Receptors, Dopamine D2, Receptors, Glutamate, Excitatory Amino Acid Agents

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review